Furthermore, in the BCIRG-001 trial, the febrile neutropenia rate for patients receiving TAC approached 25% (Martin et al, 2005), well above the recommended threshold for primary prophylaxis with G-CSF (Aapro et al, 2006; Smith et al, 2006). This evidence concerns the gene CSF3 and Decreased total neutrophil count.